PXD043359-1

PXD043359 is an original dataset announced via ProteomeXchange.

Title	Bergenin inhibits growth of human cervical cancer cells by decreasing Galectin-3 and MMP-9 expression
Description	Cervical cancer is still the leading cause of cancer mortality worldwide even after introduction of vaccine against Human papillomavirus (HPV), due to low vaccine coverage, especially in the developing world. Cervical cancer is primarily treated by Chemo/Radiotherapy, depending on the disease stage, with Carboplatin/Cisplatin-based drug regime. These drugs being non-specific, target rapidly dividing cells, including normal cells, so safer options are needed for lower off-target toxicity. Natural products offer an attractive option compared to synthetic drugs due to their well-established safety profile and capacity to target multiple oncogenic hallmarks of cancer like inflammation, angiogenesis, etc. In the current study, we investigated the effect of Bergenin (C-glycoside of 4-O-methylgallic acid), a natural polyphenol compound that is isolated from medicinal plants such as Bergenia crassifolia, Caesalpinia digyna, and Flueggea leucopyrus . Bergenin has been shown to have anti-inflammatory, anti-ulcerogenic, and wound healing properties but its anticancer potential has been realized only recently. We performed a proteomic analysis of cervical carcinoma cells treated with bergenin and found it to influence multiple hallmarks of cancers, including apoptosis, angiogenesis, and tumor suppressor proteins. It was also involved in many different cellular processes unrelated to cancer, as shown by our proteomic analysis. Further analysis showed bergenin to be a potent -angiogenic agent by reducing key angiogenic proteins like Galectin 3 and MMP-9 (Matrix Metalloprotease 9) in cervical carcinoma cells. Further understanding of this interaction was carried out using molecular docking analysis, which indicated MMP-9 has more affinity for bergenin as compared to Galectin-3. Cumulatively, our data provide novel insight into the anti-angiogenic mechanism of bergenin in cervical carcinoma cells by modulation of multiple angiogenic proteins like Galectin-3 and MMP-9 which warrant its further development as an anticancer agent in cervical cancer.
HostingRepository	PRIDE
AnnounceDate	2024-03-04
AnnouncementXML	Submission_2024-03-04_03:31:10.640.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Ravi Chauhan
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	acetylated residue; monohydroxylated residue; iodoacetamide derivatized residue
Instrument	Orbitrap Exploris 240

Revision	Datetime	Status	ChangeLog Entry
0	2023-06-27 22:04:55	ID requested
⏵ 1	2024-03-04 03:31:11	announced
2	2024-10-22 06:32:00	announced	2024-10-22: Updated project metadata.

Dataset with its publication pending

submitter keyword: Bergenin, HPV, Cervical cancer, Galectin 3, Matrix metallo protease 9

Mayank Singh
contact affiliation	Additional Professor, Deptt. of Medical Oncology (Lab), Dr BRAIRCH, AIIMS, New Delhi
contact email	mayank.osu@gmail.com
lab head
Ravi Chauhan
contact affiliation	PhD scholar
contact email	c.ravi117@gmail.com
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2024/03/PXD043359

PRIDE project URI

• PRIDE
  1. PXD043359
     1. Label: PRIDE project
     2. Name: Bergenin inhibits growth of human cervical cancer cells by decreasing Galectin-3 and MMP-9 expression